TY - JOUR
T1 - Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry
AU - Navar, Ann Marie
AU - Wang, Tracy Y.
AU - Goldberg, Anne C.
AU - Robinson, Jennifer G.
AU - Roger, Veronique L.
AU - Wilson, Peter F.
AU - Virani, Salim S.
AU - Elassal, Joesph
AU - Lee, L. Veronica
AU - Webb, Laura E.
AU - Peterson, Eric
N1 - Funding Information:
The study protocol was approved by the institutional review board (IRB) at Duke University and will receive approval by a central IRB or IRBs at each participating clinic location before initiation of any study activities. The registry is funded by Regeneron Pharmaceuticals and Sanofi Aventis. Study design was led by the Duke Clinical Research Institute with input from the steering committee (comprising experts in the field of CVD and lipid management) and the study sponsors. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the manuscript, and its final contents. Duke Clinical Research Institute will serve as the study coordinating center. This study is listed on ClinicalTrials.gov: NCT02341664.
Funding Information:
Tracy Y. Wang reports research funding from AstraZeneca, Boston Scientific, Daichi Sanyko Co., Eli Lily & Company, Gilead Sciences, Glaxo SmithKline, and Regeneron Pharmaceuticals, as well as funding from consulting services with AstraZeneca, Eli Lilly, and Premier, Inc. Anne C. Goldberg reports research funding from Merck, Genzyme/ISIS, Sanofi-Aventis, Glaxo-Smith-Kline, Regeneron Pharmaceuticals, Sanofi-Aventis, Amarin, Amgen, and Pfizer, as well as funding from consulting services with Astra-Zeneca, uniQure, Tekmira, Sanofi, and Regeneron Pharmaceuticals. Jennifer G. Robinson reports research funding from Amarin, Amgen, Astra-Zeneca, Daiichi-Sankyo, Esai, Glaxo-Smith Kline, Pfizer, Regeneron/Sanofi, and Takeda, as well as funding from consulting services with Amgen, Lilly Merck, Pfizer, Sanofi, and Regeneron Pharmaceuticals, and has served as a consultant for Amgen, Lilly Merck, Pfizer, Regeneron/Sanofi. Eric Peterson reports research funding from Eli Lilly and Janssen Pharmaceuticals, as well as funding from consulting services with Astra Zeneca, Bayer, Sanofi, and Janssen Pharmaceuticals.
Publisher Copyright:
© 2015 Mosby, Inc.
PY - 2015
Y1 - 2015
N2 - Background Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines. Objectives The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals. Study Design The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction. Conclusion The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.
AB - Background Despite improvements in diagnosis and treatment, the prevalence of hyperlipidemia among adults in the United States remains high. Data are limited on treatment patterns and patient perceptions of cardiovascular disease risk since the release of new lipid guidelines. Objectives The objectives of the PALM registry are to assess contemporary patterns of lipid-lowering therapy use among adults receiving care in a nationally representative cohort of community clinics, determine consistency of treatment with varying lipid guidelines, identify factors affecting use of lipid-lowering therapy including patient-reported statin intolerance, and assess patient and provider knowledge of cardiovascular risk reduction goals. Study Design The PALM registry will enroll 7,500 patients likely to be considered for lipid-lowering therapy from 175 cardiology, primary care, and endocrinology practices across the United States. In this cross-sectional, observational registry, a novel tablet-based platform will be used to collect patient-reported knowledge, attitudes, and beliefs regarding cardiovascular risk reduction and lipid management. Chart abstraction and core laboratory lipid levels will describe current lipid management. Provider surveys will assess perception of current lipid-lowering goals and barriers to optimal cardiovascular risk reduction. Conclusion The PALM registry will allow for better understanding of current practice patterns, patient experiences, and patient and provider attitudes toward cholesterol management for cardiovascular disease risk reduction. These data can be used to better understand gaps in care and design targeted interventions to improve uptake of lipid-lowering therapies for cardiovascular risk reduction.
UR - http://www.scopus.com/inward/record.url?scp=84954218324&partnerID=8YFLogxK
U2 - 10.1016/j.ahj.2015.08.002
DO - 10.1016/j.ahj.2015.08.002
M3 - Article
C2 - 26542493
AN - SCOPUS:84954218324
SN - 0002-8703
VL - 170
SP - 865
EP - 871
JO - American heart journal
JF - American heart journal
IS - 5
ER -